Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients

Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity

(2014) Peter Flachenecker et al.   EUROPEAN NEUROLOGY

Assessing walking disability in multiple sclerosis

(2012) Bernd C. Kieseier et al.   Multiple Sclerosis Journal

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions

(2010) Alan J Thompson et al.   LANCET NEUROLOGY

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis

(2010) Derick T Wade et al.   Multiple Sclerosis Journal

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis

(2010) RBC Kavia et al.   Multiple Sclerosis Journal

Life issues in multiple sclerosis

(2010) Rex D. Simmons   Nature Reviews Neurology

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

(2010) C. Collin et al.   NEUROLOGICAL RESEARCH

Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

(2008) John T. Farrar et al.   CLINICAL THERAPEUTICS